


c1
1. (TWICE AMENDED) A method for treating a Tumor Necrosis Factor-alpha mediated diabetic complications selected from the group consisting of retinopathy, nephropathy, neuropathy and disorders of the arteries in a mammal in need thereof, comprising administering a compound selected from the group consisting of 5-[4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione and 5-[[4-[2-(methyl-2-pyridylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione, or a pharmacologically acceptable salt thereof, to said mammal at a dose of 0.1 mg/kg to 30 mg/kg.

MARK-UP OF CLAIMS SHOWING CHANGES

1. (TWICE AMENDED) A method for treating a Tumor Necrosis Factor-alpha mediated [inflammatory disease] diabetic complications selected from the group consisting of retinopathy, nephropathy, neuropathy and disorders of the arteries in a mammal in need thereof, comprising administering [an effective therapeutic amount of] a compound [of the formula:



wherein R represents a hydrocarbon group that may be substituted or a heterocyclic group that may be substituted; Y represents a group of the formula CO , CH(OH) , or NR^3 where R^3 represents an alkyl group that may be substituted; m is 0 or 1; n is 0, 1 or 2; X represents CH or N; A represents a chemical bond or a bivalent aliphatic hydrocarbon group having 1 to 7 carbon atoms; Q represents oxygen or sulfur; R^1 represents hydrogen or an alkyl group; ring E may have further 1 to 4 substituents, which may form a ring in combination with R^1 ; L and M respectively represent hydrogen or may be combined with each other to form a chemical bond;]

selected from the group consisting of 5-[4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione and 5-[4-[2-(methyl-2-pyridylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione,


or a pharmacologically acceptable salt thereof, to said mammal [such that said Tumor Necrosis Factor-alpha mediated disease is treated] at a dose of 0.1 mg/kg to 30 mg/kg.

2. (Amended) A method according to Claim 1, wherein the heterocyclic group represented by R is a 5 to 7 membered monocyclic and heterocyclic group containing 1 to 4 hetero-atoms selected from oxygen, sulfur and nitrogen in addition to carbon as ring members or a condensed heterocyclic group.

3. (Amended) A method according to Claim 1, wherein R represents a heterocyclic group that may be substituted.

4. (Amended) A method according to Claim 3, wherein the heterocyclic group is pyridyl, oxazolyl or thiazolyl.

5. (Amended) A method according to Claim 1, wherein the partial structural formula:



6. (Amended) A method according to Claim 1, wherein X represents CH.

7. (Amended) A method according to Claim 1, wherein R¹ represents hydrogen.

8. (Amended) A method according to Claim 1, wherein L and M respectively represent hydrogen.

9. (Amended) A method according to Claim 1, wherein the compound is 5-[4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione.

10. (Amended) A method according to Claim 1, wherein the compound is (R) (+) 5-[3-[4-[2-(2-furyl)-5-methyl-4-oxazolylmethoxy]-3-methoxyphenyl]propyl]-2,4-oxazolidinedione.

13 A method according to Claim 1, wherein the compound is 5-[[4-[2-(methyl-2-pyridylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione.

14. (New) A method according to Claim 1, wherein the inflammatory disease are diabetic complications.

15. (New) A method according to Claim 14, wherein the diabetic complications is selected from the group consisting of retinopathy, nephropathy, neuropathy and disorders in the great arteries.

- ~~16.(New) A method according to Claim 1, wherein the inflammatory disease is rheumatoid arthritis.~~
- ~~17.(New) A method according to Claim 1, wherein the inflammatory disease is osteoarthritis.~~
- ~~18.(New) A method according to Claim 1, wherein the inflammatory disease is low back pain.~~
- ~~19.(New) A method according to Claim 1, wherein the inflammatory disease is gout.~~
- ~~20.(New) A method according to Claim 1, wherein the inflammatory disease is postoperative or traumatic inflammation.~~
- ~~21.(New) A method according to Claim 1, wherein the inflammatory disease is swelling.~~
- ~~22.(New) A method according to Claim 1, wherein the inflammatory disease is neuralgia.~~
- ~~23.(New) A method according to Claim 1, wherein the inflammatory disease is laryngopharyngitis.~~
- ~~24.(New) A method according to Claim 1, wherein the inflammatory disease is cystitis.~~
- ~~25.(New) A method according to Claim 1, wherein the inflammatory disease is hepatitis.~~
- ~~26.(New) A method according to Claim 1, wherein the inflammatory disease is pneumonia.~~
- ~~27.(New) A method according to Claim 1, wherein the compound is administered to the mammal at the dose of 0.1 mg/kg to 30 mg/kg.~~